Rapid weight loss affects muscle mass and can increase the risk of osteoporosis. But now there is good news for people taking weight loss medication who may be at risk. A new study indicates that the ...

Since expenditures are heavily skewed, the top 5 percent of patients by cost contribute a disproportionate amount to the mean ...

Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper ...

If Robert F. Kennedy Jr. and the Trump administration want to make America healthy again, they should let Medicare cover ...

GLP-1 drugs like Ozempic and Wegovy revolutionized weight loss, but their high cost keeps them out of reach for most ...

Gov. Ned Lamont eyed Medicaid reimbursement rates, a hospital tax restructuring and pharmaceutical costs in his biennial ...

Shares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 weight-loss drugs, Zepbound and Mounjaro, missed estimates for the second ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...

Lilly Chief Financial Officer Lucas Montarce told Reuters last month the drugmaker is trying to balance its demand-generation activities with its ability to supply more patients. The company last year ...

The AP-NORC survey shows about half of U.S. adults believe it is a good thing for adults to use Ozempic, Wegovy and similar ...

New letters urge the Centers for Medicare & Medicaid Services to expand Medicare and Medicaid to include FDA-approved ...